Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations
The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Abstract
Mutations in the p53 tumor suppressor are the most frequently observed genetic alterations in human cancer. The majority of the mutations occur in the core domain which contains the sequence-specific DNA binding activity of the p53 protein (residues 102-292), and they result in loss of DNA binding. The crystal structure of a complex containing the core domain of human p53 and a DNA binding site has been determined at 2.2 angstroms resolution and refined to a crystallographic R factor of 20.5 percent. The core domain structure consists of a beta sandwich that serves as a scaffold for two large loops and a loop-sheet-helix motif. The two loops, which are held together in part by a tetrahedrally coordinated zinc atom, and the loop-sheet-helix motif form the DNA binding surface of p53. Residues from the loop-sheet-helix motif interact in the major groove of the DNA, while an arginine from one of the two large loops interacts in the minor groove. The loops and the loop-sheet-helix motif consist of the conserved regions of the core domain and contain the majority of the p53 mutations identified in tumors. The structure supports the hypothesis that DNA binding is critical for the biological activity of p53, and provides a framework for understanding how mutations inactivate it.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Modification of any of five arginine residues that are hotspots for TP53 mutations in human cancers disables TP53 sequence-specific DNA binding (Cho, et al., 1994).”
From The Mdm network and its regulation of p53 activities: a rheostat of cancer risk (2014) · cites this paper as Cho, et al., 1994
In the citing paper
“Gly-245 in the wild type adopts unusual backbone dihedral angles (1), which are not favored when the residue is replaced by serine.”
From Hot-spot mutants of p53 core domain evince characteristic local structural changes (1999) · cites this paper as [1]
In the citing paper
“The crystal structure of p53 core domain shows that the epitope of PAb240, located in strand 7, is inaccessible to antibody binding (1), and at least a partly unfolded form is required to expose the epitope.”
From Hot-spot mutants of p53 core domain evince characteristic local structural changes (1999) · cites this paper as [1]
In the citing paper
“The guanidinium group of Arg-249 is salt-bridged to the carboxylate group of Glu-171 in L2 and backbone oxygens of Gly-245 and Met-246 (1).”
From Hot-spot mutants of p53 core domain evince characteristic local structural changes (1999) · cites this paper as [1]
In the citing paper
“suggesting the structure of p53 core domain in solution is similar to that in crystal structure (1).”
From Hot-spot mutants of p53 core domain evince characteristic local structural changes (1999) · cites this paper as [1]
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Kabsch, W., & Sander, C. (1983) · Biopolymers · doi:10.1002/bip.360221211 · Cited by 15,320
Jones, T. A., Zou, J. Y., Cowan, S. W., & Kjeldgaard, M. (1991) · Acta Crystallographica Section A Foundations of Crystallography · doi:10.1107/s0108767390010224 · Cited by 12,648
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.
Wade Harper, J. (1993) · Cell · doi:10.1016/0092-8674(93)90499-g · Cited by 5,651
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649
Principles of Nucleic Acid Structure
Saenger, W. (1984) · Springer Advanced Texts in Chemistry · doi:10.1007/978-1-4612-5190-3 · Cited by 4,150
The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53
Scheffner, M., Werness, B. A., Huibregtse, J. M., Levine, A. J., & Howley, P. M. (1990) · Cell · doi:10.1016/0092-8674(90)90409-8 · Cited by 3,995
The p53 tumour suppressor gene
Levine, A. J., Momand, J., & Finlay, C. A. (1991) · Nature · doi:10.1038/351453a0 · Cited by 3,788
Kastan, M. B., Zhan, Q., El-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., Plunkett, B. S., Vogelstein, B., & Fornace, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90593-2 · Cited by 3,047
Research works printed but not linked: 2
- SACK, J. S., JOURNAL OF MOLECULAR GRAPHICS 6: 224 (1988).
- TONRUD, D.E., ACTA CRYSTALLOGR A 43: 489 (1987).
Cited by
Items 301–400 of 2,517
Mechanism of rescue of common p53 cancer mutations by second‐site suppressor mutations
Nikolova, P. V., Wong, K., DeDecker, B., Henckel, J., & Fersht, A. R. (2000) · The EMBO Journal · doi:10.1093/emboj/19.3.370 · Cited by 152
“co-ordinates were used to display only chain B of p53 (amino acids 94–312) in a complex with the DNA double helix (Cho et al., 1994).”
BackgroundMethodInfluentialLéveillard, T., Andera, L., Bissonnette, N., Schaeffer, L., Bracco, L., Egly, J. M., & Wasylyk, B. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00506.x · Cited by 173
DNA-binding by Ig-fold proteins.
Rudolph, M. J., & Gergen, J. P. (2001) · Nature Structural Biology · doi:10.1038/87531 · Cited by 178
p53 Is Phosphorylated by CDK7-Cyclin H in a p36MAT1-Dependent Manner
Ko, L. J., Shieh, S.-Y., Chen, X., Jayaraman, L., Tamai, K., Taya, Y., Prives, C., & Pan, Z.-Q. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.12.7220 · Cited by 173
“Two types of mutants have been classified on the basis of their contribution to DNA binding (7).”
BackgroundDNA damage and oxidant stress activate p53 through differential upstream signaling pathways
Shi, T., van Soest, D. M. K., Polderman, P. E., Burgering, B. M. T., & Dansen, T. B. (2021) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2021.06.013 · Cited by 172
Verhaegh, G. W., Richard, M.-J., & Hainaut, P. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.10.5699 · Cited by 171
“This domain (residues 102 to 292) is made of two b-sheets supporting two loops and a loop-sheethelix motif, which form the DNA-binding surface (7).”
BackgroundSingle-molecule analysis of transcription factor binding at transcription sites in live cells
Morisaki, T., Müller, W. G., Golob, N., Mazza, D., & McNally, J. G. (2014) · Nature Communications · doi:10.1038/ncomms5456 · Cited by 168
p53 Isoforms: An Intracellular Microprocessor?
Khoury, M. P., & Bourdon, J.-C. (2011) · Genes & Cancer · doi:10.1177/1947601911408893 · Cited by 159
Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53
Kelly, G. L., Grabow, S., Glaser, S. P., Fitzsimmons, L., Aubrey, B. J., Okamoto, T., Valente, L. J., Robati, M., Tai, L., Fairlie, W. D., et al. (2014) · Genes & Development · doi:10.1101/gad.232009.113 · Cited by 166
“Mutations of the p53 gene, clustering around ‘‘hot spot’’ residues in the DNA-binding domain that are known to abrogate p53 function (Cho et al. 1994; Petitjean et al. 2007; Freed-Pastor and Prives 2012), were detected in Rael-BL, Sav-BL, and BL-31 and globally in ;60% of the 16 Burkitt lymphoma…”
BackgroundDynamic protein–DNA recognition: beyond what can be seen
Fuxreiter, M., Simon, I., & Bondos, S. (2011) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2011.04.006 · Cited by 167
Redox signalling and transition metals in the control of the p53 pathway
Méplan, C., Richard, M.-J., & Hainaut, P. (2000) · Biochemical Pharmacology · doi:10.1016/s0006-2952(99)00297-x · Cited by 166
Bakalkin, G., Selivanova, G., Yakovleva, T., Kiseleva, E., Kashuba, E., Magnusson, K. P., Szekely, L., Klein, G., Terenius, L., & Wiman, K. G. (1995) · Nucleic Acids Research · doi:10.1093/nar/23.3.362 · Cited by 164
DNA Charge Transport: from Chemical Principles to the Cell
Arnold, A. R., Grodick, M. A., & Barton, J. K. (2016) · Cell Chemical Biology · doi:10.1016/j.chembiol.2015.11.010 · Cited by 164
“Given the close proximity of some of these redox-active cysteine residues to the DNA (Cho et al., 1994) and the demonstrated feasibility of disulfide bond formation from a distance via DNA CT (Takada and Barton, 2005), we investigated whether p53 could be oxidized in a DNAmediated fashion (Augustyn…”
The specificity of p53 mutation spectra in sunlight induced human cancers
Daya-Grosjean, L., Dumaz, N., & Sarasin, A. (1995) · Journal of Photochemistry and Photobiology B: Biology · doi:10.1016/1011-1344(95)07130-t · Cited by 164
Drosophila p53 preserves genomic stability by regulating cell death
Sogame, N., Kim, M., & Abrams, J. M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0736384100 · Cited by 163
Current understanding of the role and targeting of tumor suppressor p53 in glioblastoma multiforme
England, B., Huang, T., & Karsy, M. (2013) · Tumor Biology · doi:10.1007/s13277-013-0871-3 · Cited by 163
“Hotspot mutations are located near the protein-DNA interface and most commonly including contact mutants/class I mutation (R248, R273) that interact with DNA, and structural mutants/class II mutations (R175, R245, R249, R282) that play critical roles in stabilizing the structure of the DNAbinding interface [13, 29].”
BackgroundAlam, S., & Kelleher, S. L. (2012) · Nutrients · doi:10.3390/nu4080875 · Cited by 163
“The p53 protein DNA binding domain is stabilized by a Zn ion, which is necessary for maintaining a functionally active conformation [90].”
BackgroundQin, K., Hou, H., Liang, Y., & Zhang, X. (2020) · BMC Cancer · doi:10.1186/s12885-020-06805-5 · Cited by 162
“72% (90/293) of all ALK-mutated NSCLC cases, which were in accordance with previous reports [50,51].”
ResultExpression of p53 oncoprotein in non-small-cell lung cancer: a favorable prognostic factor.
Lee, J. S., Yoon, A., Kalapurakal, S. K., Ro, J. Y., Lee, J. J., Tu, N., Hittelman, W. N., & Hong, W. K. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.8.1893 · Cited by 163
Molecular knots in biology and chemistry
Lim, N. C. H., & Jackson, S. E. (2015) · Journal of Physics: Condensed Matter · doi:10.1088/0953-8984/27/35/354101 · Cited by 160
Reactive Oxygen Species Induced p53 Activation: DNA Damage, Redox Signaling, or Both?
Shi, T., & Dansen, T. B. (2020) · Antioxidants & Redox Signaling · doi:10.1089/ars.2020.8074 · Cited by 160
“Three of these (Cys176, 238, and 242) coordinate a zinc atom together with His179 and, hence, are important to maintain the p53 structure (34).”
The p53-induced Gene-6 (Proline Oxidase) Mediates Apoptosis through a Calcineurin-dependent Pathway
Rivera, A., & Maxwell, S. A. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m504852200 · Cited by 160
P53 expression in altered limbal basal cells of pingueculae, pterygia, and limbal tumors
Dushku, N., & Reid, T. W. (1997) · Current Eye Research · doi:10.1076/ceyr.16.12.1179.5036 · Cited by 159
The leukemia-associated AML1 (Runx1)--CBF beta complex functions as a DNA-induced molecular clamp.
Bravo, J., Li, Z., Speck, N. A., & Warren, A. J. (2001) · Nature Structural Biology · doi:10.1038/86264 · Cited by 169
“p53 uses a bound zinc atom, in addition to salt bridge interactions, to stabilize the loops that are structurally analogous to the Runt domain βC–D loop and 'wing”
BackgroundAdenovirus E1B 55K Represses p53 Activation In Vitro
Martin, M. E. D., & Berk, A. J. (1998) · Journal of Virology · doi:10.1128/jvi.72.4.3146-3154.1998 · Cited by 159
“1) (11) that binds as a tetramer (24) to four tandem, alternatively inverted copies of a 5-bp consensus sequence (7, 9).”
BackgroundHow Many Mutant p53 Molecules Are Needed To Inactivate a Tetramer?
Chan, W. M., Siu, W. Y., Lau, A., & Poon, R. Y. C. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.8.3536-3551.2004 · Cited by 158
“The structure of the DNA binding domain consists of a large -sandwich that acts as a scaffold for three loop-based elements that contact the DNA (4).”
BackgroundDominant-negative p53 mutations selected in yeast hit cancer hot spots.
Brachmann, R. K., Vidal, M., & Boeke, J. D. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.9.4091 · Cited by 158
Transcriptional Repression by p53 through Direct Binding to a Novel DNA Element
Johnson, R. A., Ince, T. A., & Scotto, K. W. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.c100121200 · Cited by 157
Temam, S., Flahault, A., Périé, S., Monceaux, G., Coulet, F., Callard, P., Bernaudin, J., Guily, J. L. S., & Fouret, P. J. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.2.385 · Cited by 153
Brachmann, R. K., Yu, K., Eby, Y., Pavletich, N. P., & Boeke, J. D. (1998) · The EMBO Journal · doi:10.1093/emboj/17.7.1847 · Cited by 142
“1852 to be involved in any stabilizing interactions with other portions of p53 (Cho et al., 1994).”
BackgroundInfluentialSelf-citationDBD-Hunter: a knowledge-based method for the prediction of DNA–protein interactions
Gao, M., & Skolnick, J. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn332 · Cited by 154
“In the third example, we examine the target, acute myeloid leukemia 1 protein RUNT domain (38), and the template, the DBD of p53 tumor suppressor (Figure 7C) (39).”
BackgroundInhibition of DNA Topoisomerase IIα Gene Expression by the p53 Tumor Suppressor
Wang, Q., Zambetti, G. P., & Suttle, D. P. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.1.389 · Cited by 153
“The p53 protein has tetramerization, DNA binding, and transactivation functions residing in separate domains of the protein (14, 41).”
BackgroundHsp90 Regulates the Activity of Wild Type p53 under Physiological and Elevated Temperatures
Müller, L., Schaupp, A., Walerych, D., Wegele, H., & Buchner, J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m407687200 · Cited by 155
Geisler, S. B., Børresen‐Dale, A., Johnsen, H., Aas, T., Geisler, J., Akslen, L. A., Anker, G. B., & Lønning, P. E. (2003) · PubMed · Cited by 168
Biogenic Zinc Oxide Nanoparticles and Their Biomedical Applications: A Review
Jha, S., Rani, R., & Singh, S. (2023) · Journal of Inorganic and Organometallic Polymers and Materials · doi:10.1007/s10904-023-02550-x · Cited by 171
Crystal Structure of a Conserved Protease That Binds DNA: the Bleomycin Hydrolase, Gal6
Joshua‐Tor, L., Xu, H. E., Johnston, S. A., & Rees, D. C. (1995) · Science · doi:10.1126/science.7638617 · Cited by 153
Apoptosis, cancer and the p53 tumour suppressor gene
Lee, J. M., & Bernstein, A. (1995) · Cancer and Metastasis Reviews · doi:10.1007/bf00665797 · Cited by 169
“The 3 dimensional structures of the DNA binding [32] and oligomerization domains [33] have been recently solved, and the details of these structures and aspects of the domain structure of p53 have been discussed in recent reviews [34, 35].”
BackgroundCrystal Structure of the p53 Core Domain Bound to a Full Consensus Site as a Self-Assembled Tetramer
Chen, Y., Dey, R., & Chen, L. (2010) · Structure · doi:10.1016/j.str.2009.11.011 · Cited by 150
“The overall structure of the core tetramer:DNA complex is similar to that described in various modeling analyses (Cho et al., 1994; Ho et al., 2006; McLure and Lee, 1998; Pan and Nussinov , 2007) .”
InfluentialExploring the multiple roles of guardian of the genome: P53
Feroz, W., & Sheikh, A. M. A. (2020) · Egyptian Journal of Medical Human Genetics · doi:10.1186/s43042-020-00089-x · Cited by 185
Lu, H., Fisher, R. P., Bailey, P., & Levine, A. J. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.10.5923 · Cited by 152
“The p53 protein is a nuclear phosphoprotein that acts as a transcriptional activator (17, 62) with a sequence-specific DNA-binding activity (10, 17, 58, 62).”
BackgroundGeneration of medaka gene knockout models by target-selected mutagenesis
Taniguchi, Y., Takeda, S., Furutani‐Seiki, M., Kamei, Y., Todo, T., Sasado, T., Deguchi, T., Kondoh, H., Mudde, J., Yamazoe, M., et al. (2006) · Genome biology · doi:10.1186/gb-2006-7-12-r116 · Cited by 167
“Among the mutants we recovered, N220S and N220D of p53 are of particular interest, because Asn220 is located next to the Zn-binding cysteine in loop 3, which is important for stabilization of p53 folding [31].”
Backgroundp53: a Glimpse at the Puppet Behind the Shadow Play
Friend, S. H. (1994) · Science · doi:10.1126/science.8023155 · Cited by 152
Gouas, D. A., Shi, H., & Hainaut, P. L. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.02.057 · Cited by 151
Structural Details on mdm2-p53 Interaction
Chi, S.-W., Lee, S.-H., Kim, D.-H., Ahn, M.-J., Kim, J.-S., Woo, J.-Y., Torizawa, T., Kainosho, M., & Han, K.-H. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m508578200 · Cited by 150
Koduru, P. R. K., Raju, K., Vadmal, V., Menezes, G., Shah, S., Susin, M., Kolitz, J. E., & Broome, J. D. (1997) · Blood · doi:10.1182/blood.v90.10.4078 · Cited by 148
Interaction of p53 with Its Consensus DNA-Binding Site
Wang, Y., Schwedes, J. F., Parks, D., Mann, K., & Tegtmeyer, P. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.4.2157 · Cited by 149
“The cylinders beneath the DNA-binding domains of p53 represent loop-sheethelix regions of p53 that make specific base contacts in the major grooves of a consensus DNA site (3).”
BackgroundInfluentialThe C terminus of p53 binds the N-terminal domain of MDM2
Poyurovsky, M. V., Katz, C., Laptenko, O., Beckerman, R., Lokshin, M., Ahn, J., Byeon, I.-J. L., Gabizon, R., Mattia, M., Zupnick, A., et al. (2010) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1872 · Cited by 149
“p53 coexpressed with p300 is highly acetylated, as shown by a gain of reactivity with a Pan-acetyl antibody and corresponding loss of reactivity with an antibody PAb 421 that recognizes unmodified p53 CTD 372–382 (refs”
BackgroundHartwig, A., Asmuß, M., Blessing, H., Hoffmann, S. A., Jahnke, G., Khandelwal, S. K., Pelzer, A., & Bürkle, A. (2002) · Food and Chemical Toxicology · doi:10.1016/s0278-6915(02)00043-1 · Cited by 169
Resnick, M. A., & Inga, A. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1633803100 · Cited by 149
p53 GENE MUTATIONS AND PHOTOCARCINOGENESIS
Nataraj, A. J., Trent, J. C., & Ananthaswamy, H. N. (1995) · Photochemistry and Photobiology · doi:10.1111/j.1751-1097.1995.tb05262.x · Cited by 167
p53 gene mutation: software and database
Beroud, C. (1998) · Nucleic Acids Research · doi:10.1093/nar/26.1.200 · Cited by 147
Tumor-Derived p53 Mutants Induce NF-κB2 Gene Expression
Scian, M. J., Stagliano, K. E. R., Anderson, M. A. E., Hassan, S., Bowman, M., Miles, M. F., Deb, S. P., & Deb, S. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.22.10097-10110.2005 · Cited by 148
“It is interesting to note that p53-R273H also induces chemoresistance in our hands, although this mutant apparently does not have an altered conformation of its DNA-binding domain (15) and therefore, according to some reports, does not bind to p73 or p63 efficiently (33, 47, 74, 75).”
BackgroundExcision of 3′ Termini by the Trex1 and TREX2 3′→5′ Exonucleases
Mazur, D. J., & Perrino, F. W. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m100623200 · Cited by 147
Structures of thymidine kinase 1 of human and mycoplasmic origin
Welin, M., Kosinska, U., Mikkelsen, N.-E., Carnrot, C., Zhu, C., Wang, L., Eriksson, S., Munch‐Petersen, B., & Eklund, H. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0406332102 · Cited by 153
The Initiation of Simian Virus 40 DNA ReplicationIn Vitro
Bullock, P. A., & Simmons, D. T. (1997) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409239709082001 · Cited by 166
Lilyestrom, W., Klein, M. G., Zhang, R., Joachimiak, A., & Chen, X. S. (2006) · Genes & Development · doi:10.1101/gad.1456306 · Cited by 132
“In the crystal structure of the p53–DNA complex, the L3 loop of p53 makes several important contacts with DNA (Cho et al. 1994).”
BackgroundInfluentialStrategies for manipulating the p53 pathway in the treatment of human cancer
Hupp, T. R., Lane, D. P., & Ball, K. L. (2000) · Biochemical Journal · doi:10.1042/0264-6021:3520001 · Cited by 148
Functional role of inorganic trace elements in angiogenesis—Part II: Cr, Si, Zn, Cu, and S
Saghiri, M. A., Asatourian, A., Orangi, J., Sorenson, C. M., & Sheibani, N. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.05.011 · Cited by 146
“, the tumor suppresor effect of protein, stopping the progression of cancer cell itosis, and promoting cell death [53,54].”
BackgroundRescue of mutants of the tumor suppressor p53 in cancer cells by a designed peptide
Issaeva, N., Friedler, A., Bozko, P., Wiman, K. G., Fersht, A. R., & Selivanova, G. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1835733100 · Cited by 118
The Role of p53 in Cell Cycle Regulation
Shaw, P. H. (1996) · Pathology - Research and Practice · doi:10.1016/s0344-0338(96)80088-4 · Cited by 169
p53 Isoforms and Their Implications in Cancer
Vieler, M., & Sanyal, S. (2018) · Cancers · doi:10.3390/cancers10090288 · Cited by 140
“The DBD binds to the major groove of the DNA with the highly-conserved long helix H2 (residues 270–286) [31] by an induced fit mechanism [32].”
Background(2002) · PubMed · Cited by 143
Craig, A. L., Burch, L. R., VOJTESEK, B., MIKUTOWSKA, J., Thompson, A. M., & Hupp, T. R. (1999) · Biochemical Journal · doi:10.1042/0264-6021:3420133 · Cited by 147
Kaelin, W. G. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.7.594 · Cited by 173
Puca, R., Nardinocchi, L., Givol, D., & D’Orazi, G. (2010) · Oncogene · doi:10.1038/onc.2010.183 · Cited by 153
Pharmacological reactivation of mutant p53: from protein structure to the cancer patient
Wiman, K. G. (2010) · Oncogene · doi:10.1038/onc.2010.188 · Cited by 134
“Its structure when bound to DNA was determined by X-ray crystallography (Cho et al., 1994).”
BackgroundHow loops, β sheets, and α helices help us to understand p53
Prives, C. L. (1994) · Cell · doi:10.1016/0092-8674(94)90519-3 · Cited by 141
The UMD TP53 database and website: update and revisions
Hamroun, D., Kato, S., Ishioka, C., Claustres, M., Béroud, C., & Soussi, T. (2006) · Human Mutation · doi:10.1002/humu.20269 · Cited by 140
“Two classes of mutations have been distinguished on the basis of various in vitro assays and the three-dimensional structure of the protein [Cho et al., 1994]: class I mutations, exemplified by mutants at codon 248 (7.”
BackgroundKinetic Instability of p53 Core Domain Mutants
Friedler, A., Veprintsev, D. B., Hansson, L. O., & Fersht, A. R. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m302458200 · Cited by 133
Rescue of mutant p53 transcription function by ellipticine
Peng, Y., Li, C., Chen, L., Sebti, S. M., & Chen, J. (2003) · Oncogene · doi:10.1038/sj.onc.1206777 · Cited by 151
“Conformation mutants are thought to cause partial unfolding or misfolding of the core domain, resulting in increased sensitivity to in vitro protease digestion and exposure of the Pab240 antibody epitope that is normally packed in the hydrophobic core (Bargonetti et al., 1993; Cho et al., 1994).”
BackgroundReactivation of Mutant p53 through Interaction of a C-Terminal Peptide with the Core Domain
Selivanova, G., Ryabchenko, L., Jansson, E., Iotsova, V., & Wiman, K. G. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.5.3395 · Cited by 111
“, Arg 175 and Arg 249 (structural mutations) (4).”
BackgroundMethodInfluentialHow mutations shape p53 interactions with the genome to promote tumorigenesis and drug resistance
Stiewe, T., & Haran, T. E. (2018) · Drug Resistance Updates · doi:10.1016/j.drup.2018.05.001 · Cited by 147
Redox Regulation of Transcription Factors in Plant Stress Acclimation and Development
Dietz, K. (2013) · Antioxidants and Redox Signaling · doi:10.1089/ars.2013.5672 · Cited by 165
“On oxidation, P53 loses its DNA binding ability (15).”
Transcriptional Regulation by Wild-Type and Cancer-Related Mutant Forms of p53
Pfister, N. T., & Prives, C. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026054 · Cited by 137
“…the DNA-binding site and conformational mutants (e.g., R175H) that are partly unfolded leading to loss of zinc coordination and general DNA binding (Cho et al. 1994; Joerger et al. 2005, 2006). p53 hotspot mutant proteins have been reported to associate with chromatin and alter a cell’s…”
BackgroundInfluentialBykov, V. J. N., Zhang, Q., Zhang, M., Ceder, S., Abrahmsen, L., & Wiman, K. G. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00021 · Cited by 137
“Among the 10 cysteine residues in p53’s core domain, four – Cys182, Cys229, Cys242, and Cys277 – are exposed on the surface of the protein and accessible for modification in correctly folded p53 (20, 21).”
BackgroundPerrone, F., Bossi, P., Cortelazzi, B., Locati, L. D., Quattrone, P., Pierotti, M. A., Pilotti, S., & Licitra, L. F. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.4170 · Cited by 137
Understanding p53 functions through p53 antibodies
Sabapathy, K., & Lane, D. P. (2019) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjz010 · Cited by 137
“This sequence is buried in the crystal structure of the DBD and hidden from the surface of p53 (Cho et al., 1994).”
BackgroundThe p53 protein family and radiation sensitivity: Yes or no?
Cuddihy, A. R., & Bristow, R. G. (2004) · Cancer and Metastasis Reviews · doi:10.1023/b:canc.0000031764.81141.e4 · Cited by 153
“Within this central core are four evolutionarily conserved regions that play a role in facilitating DNA–protein interactions [34].”
BackgroundThe p53 network in lung carcinogenesis
Robles, A. I., Linke, S. P., & Harris, C. C. (2002) · Oncogene · doi:10.1038/sj.onc.1205563 · Cited by 154
“The residues involved directly in contact with DNA or indirectly in the correct folding of p53 coincide with Oncogene p53 mutational hotspots in cancer (Cho et al., 1994).”
BackgroundInsights into cancer therapeutic design based on p53 and TRAIL receptor signaling
El‐Deiry, W. S. (2001) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4400943 · Cited by 150
EUKARYOTIC TRANSCRIPTION FACTOR-DNA COMPLEXES
Patikoglou, G., & Burley, S. K. (1997) · Annual Review of Biophysics and Biomolecular Structure · doi:10.1146/annurev.biophys.26.1.289 · Cited by 133
Ang, H. C., Joerger, A. C., Mayer, S., & Fersht, A. R. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m604209200 · Cited by 134
Campomenosi, P., Monti, P., Aprile, A., Abbondandolo, A., Frébourg, T., Gold, B. I., Crook, T., Inga, A., Resnick, M. A., Iggo, R. D., et al. (2001) · Oncogene · doi:10.1038/sj.onc.1204468 · Cited by 150
“…cell cycle arrest while being defective in induction of Bax and PIG3-mediated aLocalization according to the topological diagram of the core domain (Cho et al., 1994). bPercentage of species in which the speci®c codon is identical to that observed in the human cDNA (data from Soussi and May,…”
MethodLuo, J., Yang, Q., Tong, W., Hergenhahn, M., Wang, Z., & Hollstein, M. C. (2001) · Oncogene · doi:10.1038/sj.onc.1204080 · Cited by 146
“…regulation of the modi®ed p53 gene (p53KI) have been achieved in homozygous hupki mice, despite the chimeric nature of the allele and the notorious sensitivity of p53 to minor sequence alterations not directed by evolution (Hainaut and Hollstein, 2000; Brachmann et al., 1998; Cho et al., 1994).”
BackgroundWatanabe, T., & Sullenger, B. A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.150104097 · Cited by 130
The missing Zinc: p53 misfolding and cancer
Loh, S. N. (2010) · Metallomics · doi:10.1039/c003915b · Cited by 133
Held, J. M., Danielson, S. R., Behring, J. B., Atsriku, C., Britton, D. J., Puckett, R. L., Schilling, B., Campisi, J., Benz, C. C., & Gibson, B. W. (2010) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m900643-mcp200 · Cited by 133
“ies have hypothesized that, because Cys182 lies at the dimerdimer interface of the p53 tetramer (33), oxidation of this”
BackgroundNicholls, C. D., McLure, K. G., Shields, M. A., & Lee, P. W. K. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m108815200 · Cited by 133
Males absent on the first (MOF): from flies to humans
Rea, S., Xouri, G., & Akhtar, A. (2007) · Oncogene · doi:10.1038/sj.onc.1210607 · Cited by 135
“It is interesting to note that this residue, which is located within the DNA-binding domain of p53 (Cho et al., 1994), has also been found to be mutated in a limited number of cancers (Meyers et al.”
BackgroundPharmaceutical research in molecular oncology
Gibbs, J. (1994) · Cell · doi:10.1016/0092-8674(94)90189-9 · Cited by 132
The Processing of Holliday Junctions by BLM and WRN Helicases Is Regulated by p53
Yang, Q., Zhang, R., Wang, X. W., Spillare, E. A., Linke, S. P., Subramanian, D., Griffith, J. D., Li, J. L., Hickson, I. D., Shen, J. C., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m204111200 · Cited by 136
Covalent and noncovalent modifiers of the p53 protein
Jayaraman, L., & Prives, C. L. (1999) · Cellular and Molecular Life Sciences · doi:10.1007/s000180050271 · Cited by 150
p53: The Attractive Tumor Suppressor in the Cancer Research Field
Ozaki, T., & Nakagawara, A. (2011) · BioMed Research International · doi:10.1155/2011/603925 · Cited by 131
“These mutations disrupted the whole conformation of the sequence-specific DNA-binding domain of p53 and resulted in the loss of its sequence-specific DNAbinding ability [23].”
BackgroundSoini, Y., Chia, S.-C., Bennett, W. P., Groopman, J. D., Wang, J.-S., DeBenedetti, V. M. G., Cawley, H., Welsh, J.-A., Hansen, C., Bergasa, N. V., et al. (1996) · Carcinogenesis · doi:10.1093/carcin/17.5.1007 · Cited by 128
“Based on X-ray crystallography studies of p53 the codon 249 region has been proposed to be important for p53 protein binding to its sequence-specific consensus site in DNA ( 17 ).”
BackgroundMunsch, D., Watanabe-Fukunaga, R., Bourdon, J.-C., Nagata, S., May, E., Yonish-Rouach, E., & Reisdorf, P. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.6.3867 · Cited by 131
p53 as a hub in cellular redox regulation and therapeutic target in cancer
Eriksson, S. E., Ceder, S., Bykov, V. J. N., & Wiman, K. G. (2019) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjz005 · Cited by 123
“Thus, as mutant p53 prolongs TNF-α-induced NFκB signaling (Cooks et al., 2013), it is conceivable that mutant p53 can upregulate Nrf2 via NFκB.”
BackgroundWang, Y., Suh, Y.-A., Fuller, M. Y., Jackson, J. G., Xiong, S., Terzian, T., Quintás-Cardama, A., Bankson, J. A., El-Naggar, A. K., & Lozano, G. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44504 · Cited by 131
p53 oligomerization and DNA looping are linked with transcriptional activation.
Stenger, J. E., Tegtmeyer, P., Mayr, G. A., Reed, M., Wang, Y., Wang, P., Hough, P. V., & Mastrangelo, I. A. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06947.x · Cited by 100
Integrating mutation data and structural analysis of the TP53 tumor-suppressor protein
Martin, A. C. R., Facchiano, A. M., Cuff, A. L., Hernandez-Boussard, T., Olivier, M., Hainaut, P., & Thornton, J. M. (2002) · Human Mutation · doi:10.1002/humu.10032 · Cited by 129
“Some 20% of all mutations are concentrated at five hotspot codons in the core domain: 175, 245, 248, 249, and 273 (standard human numbering scheme as used in Protein Databank file 1tsr [Cho et al., 1994] and throughout this work).”
BackgroundMethodInfluentialTwo sequence motifs from HIF-1α bind to the DNA-binding site of p53
Hansson, L. O., Friedler, A., Freund, S., Rüdiger, S., & Fersht, A. R. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.122347199 · Cited by 129
Metadata
- Authors
- Cho, Y., Gorina, S., Jeffrey, P. D., & Pavletich, N. P.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Venue
- Science
- Published
- 1994-07-15
- Volume
- 265
- Issue
- 5170
- Pages
- 346-355
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2096276671
- Semantic Scholar
- 11096f3b08e172ce5e261795b6749818ee59c03d
- Cited by
- 2,551
- References
- 62
- Citations by year
- 2026: 62 · 2025: 52 · 2024: 40 · 2023: 64 · 2022: 61 · 2021: 73 · 2020: 67 · 2019: 62 · 2018: 61 · 2017: 54 · 2016: 64 · 2015: 62 · 2014: 81 · 2013: 78 · 2012: 68
- FWCI
- 64.38
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Open Access System for Information Sharing (Pohang University of Science and Technology) (submittedVersion)
- Funders
- National Cancer Institute (NCI CA08748-29)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Structure and Dynamics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Structural Biology › Enzyme Structure and Function
- Keywords
- p53 tumor suppressor, p53 core domain, DNA binding, zinc coordination, beta-sandwich, cancer genetics
- MeSH terms
- Amino Acid Sequence, Base Sequence, Binding Sites, Computer Graphics, Crystallization, DNA, Hydrogen Bonding, Models, Molecular, Molecular Sequence Data, Mutation, Nucleic Acid Conformation, Protein Conformation, Genes, p53, Tumor Suppressor Protein p53, Protein Structure, Secondary, Crystallography, X-Ray
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.